Hospital

The FDA's approval includes the group indication for all current and future EGFR TKIs, including erlotinib, osimertinib, and gefitinib.

HOPA DEI Committee chair Kamakshi Rao, PharmD, BCOP, FASHP, noted that on the DEI journey ahead, the oncology pharmacist should be front and center as part of the treatment team.

The analysis found that individuals in underserved communities were as much as 34% less likely to be vaccinated against COVID-19.

Calcitriol may offer protection from the harmful effects of the chemical in drinking water, analysis shows.

The protein is vitally important and could be a prognostic indicator and potential therapeutic target.

Alex Barker founded The Happy PharmD to provide career coaching and career development classes, and since 2017, the company has helped over 1,500 pharmacists.

From newsworthy moments to groundbreaking research, these are the most popular articles in the cholangiocarcinoma space, published on Pharmacy Times® during 2022.

A controlled substances diversion prevention program (CSDPP) that aligns with the revised ASHP guidelines is critical to ensure patients are protected from occurrences of drug diversion.

An anti-cancer vaccine that is now in clinical trials shows promise as a preventative agent. However, experts are unsure when it will be widely available.

In addition to ongoing staffing patterns and new technology, an expert said pharmacies will have to adapt to new ways of educating students and staff.

Recommendations for the management of bile duct cancer benefit authorities, patients, and physicians, but investigators say more research is needed.

The FDA granted Priority Review to both applications and set a Prescription Drug User Fee Act goal date for each application of April 21, 2023.

From newsworthy moments to groundbreaking research, these are the most popular articles in the intravenous immunoglobulin space, published on Pharmacy Times® during 2022.

Financial assistance platforms improve patient outcomes and the pharmacy bottom line.

The additional indication expands its therapeutic role beyond advanced non-small cell lung cancer.

Age was a contributing factor of chronic kidney disease and albuminuria in patients with type 1 and type 2 diabetes.

Investigators establish that audio and/or facial video features have been most analyzed by machine learning, followed by electroencephalography signals.

Identifying how survivors adjust to their cancer may help health care providers provide tailored self-management skills.

The median progression-free survival and overall survival were 7.4 and 14.7 months, respectively, in chemotherapy-naïve patients with advanced or recurrent biliary tract cancer.

Treatment observably eased obsessive-compulsive disorder symptom severity in young patients, however, symptoms still caused students to be absent from school at least 2 days every month.

Traditionally, endemic fungi are characterized by geographical distribution, however, disease-causing fungi may infect people beyond these havens.

Merck and Moderna’s adjuvant melanoma treatment shows reduced risk of recurrence or death by 44% compared with pembrolizumab alone.

A randomized study of renin-angiotensin system inhibitors in advanced chronic kidney disease found that patients who continued receiving therapy had similar outcomes to those who discontinued treatment.

There are limited data on the efficacy of boosters for preventing infection and death in nursing home residents, but the findings suggest that boosters may have significantly reduced COVID-19–associated morbidity and mortality in this population.

Study findings provide insight into factors preventing the uptake of pre-exposure prophylaxis for HIV among Black female adolescents and emerging adults and provide potential strategies to improve uptake.

Although quality of life has significantly improved for patients with HIV, there are several factors influencing how we provide care and treat patients now and in the future.

While the use of direct-acting antiviral treatment for hepatitis C virus increased from 2014 to 2018, treatment rates have declined since 2019 and remain suboptimal.

Ponatinib could be the first targeted treatment approved in the United States for Philadelphia chromosome-positive acute lymphoblastic leukemia.

Following the positive phase 3 results, GSK anticipates regulatory submissions in the first half of 2023.

The updated recommendations during a surge in cases emphasize the need to enhance emergency readiness daily to not interrupt continuous care of children’s mental and physical well-being.